← Back to Analyst Consensus 
TRDA Buy
Entrada Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 8, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 8, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Apr 6, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Feb 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Feb 11, 2026 | Guggenheim | initiate | — → Buy | $20 | 52% |
| May 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Mar 31, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Feb 25, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Feb 4, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Dec 5, 2024 | Roth MKM | initiate | — → Buy | $29 | 52% |
| Nov 6, 2024 | Oppenheimer | maintain | Outperform → Outperform | $28 | 52% |
| Nov 6, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Aug 26, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $25 | 52% |
| Aug 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Jun 25, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $18 | 44% |
| Mar 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Jan 5, 2024 | Oppenheimer | initiate | — → Outperform | $22 | 52% |
| Nov 27, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Sep 22, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Aug 9, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Aug 2, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| May 24, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Apr 3, 2023 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
| Nov 8, 2022 | Goldman Sachs | maintain | — → Neutral | $18 | 54% |
| Aug 16, 2022 | Goldman Sachs | maintain | — → Neutral | $13 | 54% |
| May 24, 2022 | Goldman Sachs | maintain | — → Neutral | $10 | 54% |
| Nov 24, 2021 | Evercore ISI Group | initiate | — → Outperform | $0 | 58% |
| Nov 23, 2021 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Nov 23, 2021 | Goldman Sachs | initiate | — → Neutral | $29 | 54% |
Price Target Trend
May 25, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days